Medtronic Q1 Revenue Jumps 13.7% on Strong Device Demand
On Tuesday, September 1, 2026, Medtronic plc (NYSE: MDT) reported fiscal first-quarter results for the period ended July 31, 2026. The medical device giant posted revenue of $9.8 billion, a 13.7% increase as reported and on an organic basis, beating its own guidance midpoint by roughly 200 basis points. The performance underscores sustained momentum across its cardiovascular and neuroscience portfolios.
Cardiovascular Segment Leads With 18.9% Growth
Cardiovascular, Medtronic’s largest segment, grew 18.9% in the quarter, driven by two standout businesses. Cardiac Rhythm Management expanded 15%, while Cardiac Ablation Solutions surged 88%, reflecting strong adoption of the Affera mapping and ablation system. In July 2026, Medtronic announced an expanded CE Mark for the Affera system and Sphere-9 catheter to treat ventricular arrhythmias, broadening its addressable market in electrophysiology.
This growth is not just a blip—it reflects a durable shift toward minimally invasive procedures. The 88% jump in ablation solutions indicates that physicians are increasingly choosing advanced catheter-based treatments over traditional surgical options, a trend that could persist as clinical evidence accumulates.
Neuroscience and Medical Surgical Post Double-Digit Gains
Neuroscience revenue rose 9.3%, with Cranial and Spinal Technologies up 13% and enabling technologies (including robotics and navigation) growing in the low-20s. Pelvic Health grew 15%, helped by the Altaviva system, which continues to gain traction in urology and gynecology.
Medical Surgical delivered a 10.2% increase, with Surgical up 9% and Acute Care & Monitoring up 14%. The broad-based strength across segments suggests that hospital spending on advanced medical technologies remains robust, even as macroeconomic headwinds persist.
EPS Beats Guidance, FY27 Outlook Raised
GAAP diluted EPS came in at $1.14, while non-GAAP diluted EPS was $1.45, ahead of company guidance. Management raised its FY27 organic revenue growth outlook by 50 basis points to a range of 7.25% to 7.75%, and lifted non-GAAP EPS guidance to $5.94–$6.00, up from prior expectations.
The EPS beat was driven by operational leverage and favorable product mix, not just revenue upside. This suggests that Medtronic is managing costs effectively while scaling its higher-margin innovation portfolio, a positive signal for margin expansion through fiscal 2027.
Strategic Moves: Pi-Cardia Investment and Robotics Partnership
Beyond the quarter, Medtronic announced a strategic investment in Pi-Cardia, a company developing leaflet modification technology for structural heart procedures. This aligns with Medtronic’s push into transcatheter valve solutions and could complement its existing structural heart franchise.
Additionally, Medtronic formed a strategic partnership with Cornerstone Robotics to expand global access to robotic-assisted surgery. This move intensifies competition with Intuitive Surgical and Stryker’s Mako system, potentially reshaping the surgical robotics landscape. Investors should watch how quickly Medtronic can integrate these technologies into its installed base.
Market Context and Valuation Check
Medtronic’s 13.7% organic growth outpaces the broader med-tech sector, where average growth has hovered around 5–7% in recent quarters. The company’s diversified portfolio and innovation pipeline are clearly paying off, but the stock’s reaction will depend on whether this growth is sustainable. With a forward P/E in the mid-teens, Medtronic remains reasonably valued relative to faster-growing peers like Boston Scientific.
However, investors should note that Medtronic’s guidance implies a deceleration from Q1’s pace—the full-year midpoint of 7.5% is well below the 13.7% reported in the quarter. This is partly due to easier comps in Q1 and timing of product launches, but it also signals that Q1’s strength may not be repeated every quarter.
What to Watch: Q2 Revenue Growth and Robotics Uptake
Next, investors should focus on Medtronic’s fiscal Q2 results, expected in late November 2026, to see if organic growth stays above 8%. Any commentary on the Cornerstone Robotics partnership’s timeline and early adoption of the Affera system in Europe will be key. A sustained growth rate above 8% would confirm that Medtronic’s turnaround is structural, while a drop below 6% would raise doubts about the durability of its device cycle.
Comments are closed.